Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
- Vivian A. Fonseca, MD1,
- Julio Rosenstock, MD2,
- Antonia C. Wang, PHD3,
- Kenneth E. Truitt, MD3 and
- Michael R. Jones, PHD4
- 1Tulane University Health Sciences Center, New Orleans, Louisiana
- 2Dallas Diabetes and Endocrine Center, Dallas, Texas
- 3Daiichi Sankyo Pharma Development, Edison, New Jersey
- 4Daiichi Sankyo, Inc., Parsippany, New Jersey
- Corresponding author: Vivian Fonseca, vfonseca{at}tulane.edu
Abstract
OBJECTIVE—Hyperglycemia is a risk factor for microvascular complications and may increase the risk of cardiovascular disease in patients with type 2 diabetes. This study tested the LDL cholesterol–lowering agent colesevelam HCl (colesevelam) as a potential novel treatment for improving glycemic control in patients with type 2 diabetes on sulfonylurea-based therapy.
RESEARCH DESIGN AND METHODS—A 26-week, randomized, double-blind, placebo-controlled, parallel-group, multicenter study was carried out between August 2004 and August 2006 to evaluate the efficacy and safety of colesevelam for reducing A1C in adults with type 2 diabetes whose glycemic control was inadequate (A1C 7.5–9.5%) with existing sulfonylurea monotherapy or sulfonylurea in combination with additional oral antidiabetes agents. In total, 461 patients were randomized (230 given colesevelam 3.75 g/day and 231 given placebo). The primary efficacy measurement was mean placebo-corrected change in A1C from baseline to week 26 in the intent-to-treat population (last observation carried forward).
RESULTS—The least squares (LS) mean change in A1C from baseline to week 26 was −0.32% in the colesevelam group and +0.23% in the placebo group, resulting in a treatment difference of −0.54% (P < 0.001). The LS mean percent change in LDL cholesterol from baseline to week 26 was −16.1% in the colesevelam group and +0.6% in the placebo group, resulting in a treatment difference of −16.7% (P < 0.001). Furthermore, significant reductions in fasting plasma glucose, fructosamine, total cholesterol, non–HDL cholesterol, and apolipoprotein B were demonstrated in the colesevelam relative to placebo group at week 26.
CONCLUSIONS—Colesevelam improved glycemic control and reduced LDL cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 5 May 2008. Clinical trial reg. no. NCT00147758, clinicaltrials.gov.
V.F. has received research support from GlaxoSmithKline, Novartis, Novo-Nordisk, Takeda, Astra-Zeneca, Pfizer, sanofi-aventis, Eli Lilly, Daiichi-Sankyo, the National Institutes of Health, and the American Diabetes Association and honoraria for consulting fees and lectures from GlaxoSmithKline, Novartis, Takeda, Pfizer, sanofi-aventis, and Eli Lilly.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Received February 7, 2008.
- Accepted April 25, 2008.
- DIABETES CARE
